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Background: Epidemiological data on hepatitis B virus (HBV) infection among pregnant women in Cameroon are
very scarce, especially in the rural milieu. The purpose of this study was to determine the prevalence and factors
associated with HBV infection, and the infectivity of rural pregnant women in the Far North Region of Cameroon.
Methods: A cross-sectional study was conducted in three rural health facilities of the Guidiguis health district between
December 2013 and March 2014. We consecutively recruited 325 pregnant women attending antenatal consultations. A
pretested questionnaire was used to collect socio-demographic data and factors associated with HBV infection.
The presence of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and human immunodeficiency
virus (HIV) were determined using commercial test strips. Regression analyses were used to assess correlates of
HBV infection.
Results: The mean age was 24.4 (SD5.6) years. Most women were married (97.2%) and housewives (96.4%), with
less than secondary education level (80%). Only 4 women (1.2%) had been vaccinated against HBV. Thirty-three
women (10.2%) were HBsAg-positive, of whom 4 (12.1%) were positive to HBeAg. The prevalence of HIV infection
was 2.5% (8/325). Overall, 5 (1.5%) women were co-infected with HIV and HBV. Independent correlates of HBV infection
included history of blood transfusion (adjusted odd ratio 12.59, 95% CI 1.46-108.89; p = 0.021) and concurrent infection
by HIV (adjusted odd ratio 22.53, 95% CI 4.76-106.71; p < 0.0001).
Conclusion: The prevalence of HBV infection among pregnant women in this rural milieu is high. History of blood
transfusion and HIV infection are highly associated with HBV infection. The relative low rate of women positive to both
HBsAg and HBeAg suggests that perinatal transmission of HBV might not be the prevailing mode of HBV transmission
in this area.
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Hepatitis B virus (HBV) infection is a major health problem
worldwide owing to its high prevalence and significant
morbidity and mortality. There are about 2 billion people
who have been exposed to HBV worldwide, and about 360
million chronic carriers [1]. More than 780,000 people die
annually as a result of HBV-related liver diseases including* Correspondence: noubiapjj@yahoo.fr
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unless otherwise stated.chronic hepatitis, cirrhosis and hepatocellular carcinoma,
making HBV infection the 10th leading cause of death glo-
bally [1,2]. The burden of HBV is highest in Africa where
approximately 65 million chronically infected individuals
live, with prevalence rates ranging from less than 7% to
more than 20% in some countries [3,4].
Mother-to-child transmission (MTCT) of HBV is re-
sponsible for more than one third of chronic HBV infec-
tions globally [5]. Indeed, perinatal transmission seems
to be predominant in high-prevalence areas such as sub-
Saharan African countries [6]. Children born to mothers
positive for hepatitis B surface antigen (HBsAg) andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of perinatal acquisition of HBV infection, and up to 90%
of perinatal infections evolve towards chronicity com-
pared to nearly 5% of adult infections [7]. Prevention of
perinatal transmission of HBV is therefore crucial to
tackle the burden of the disease in high endemic sub-
Saharan African areas. Effective strategies for reducing
the incidence of chronic infections include maternal
screening combined with post-exposure prophylaxis
consisting of HBV vaccination immediately after delivery
in all children born to HBsAg positive mothers, ideally
with immunoglobulin prophylaxis [8].
Chronic HBV is highly endemic (prevalence ≥ 8%) in
Cameroon, a central African country [9]. However, data on
the epidemiology of HBV infection in this country are
scarce, and those available are mostly from urban areas.
In recent studies, Noubiap et al. and Fouelifack Ymele
et al. reported HBsAg prevalence as high as 10.1% and
12.1% among healthy blood donors, respectively [10,11].
Frambo et al. and Fomulu et al. estimated the prevalence
of HBsAg in pregnancy at 9.7% and 7.7%, respectively
[12,13]. Despite the perinatal burden of HBV, pregnant
women in Cameroon are not routinely screened in most
health facilities. Moreover, routine vaccination of infants
against HBV within the national Expanded Program on
Immunization starts at 6 weeks [12].
This study aimed to determine the prevalence and factors
associated with HBV infection, and the infectivity of rural
pregnant women in the Far North region of Cameroon.
Methods
Ethical considerations
This study was performed in accordance with the guide-
lines of the Helsinki Declaration and was approved by the
Regional Office of the Ministry of Public Health (MOH) for
the Far North region, acting as Ethics Committee. Written
informed consent was obtained from all participants. HIV-
and HBV-infected women were referred to health officers
for appropriate management according to local protocols.
Setting and study population
This was a cross-sectional study conducted between
December 2013 and March 2014 in three rural health
facilities at Toulom, Dziguilao and Guidiguis. These vil-
lages are part of the Guidiguis health district which
covers a population of 150,963 inhabitants and is lo-
cated 135 km south-east of Maroua, the administrative
headquarter of the Far North Region of Cameroon.
The study population comprised all pregnant women
who attended antenatal care in the selected health centers
during the study period. We used the Window Program for
Epidemiologist version 11.25 to calculate the minimal re-
quired sample size. Assuming a 9.7% prevalence of HBsAg
among pregnant women as found in a previous study inCameroon [12], a 5% margin of error and a 95% confidence
interval, the minimal sample size of the study population
was 135 participants. We consecutively recruited all preg-
nant women consenting to participate in the study until we
reached a target sample size of 325 in the three sites.Data collection and laboratory investigation
A structured pretested questionnaire was used to collect
socio-demographic information and data on risk factors for
HBV infection among participants. Upon completion of the
questionnaire, 5 ml of venous blood was aseptically col-
lected by venipuncture into an Ethylene Di-amine Tetra-
acetic Acid (EDTA) tube. The plasma obtained from each
sample was tested for the presence of HBsAg using a
commercial test strip, the DiaSpot One Step Hepatitis
B test (DiaSpot Diagnostics, USA), according to the
manufacturer’s instructions. All samples tested positive
were retested for confirmation using the same kit.
There were no discordant results. Samples confirmed
positive for HBsAg were further tested for HBeAg
using a commercial test strip, the DiaSpot One Step
HBeAg test (DiaSpot Diagnostics, USA). We also tested
all blood samples for HIV according to the national
screening algorithm. Accordingly, samples were first
screened with an anti-HIV antibody rapid test, the Deter-
mine HIV-1/2 (Abbott Laboratories, IL, USA), and positive
samples were retested with the OraQuick ADVANCE®
Rapid HIV-1/2 Antibody Test (OraSure Technologies Inc,
Pennsylvania, USA). Samples giving discrepant HIV results
were sent for confirmation by enzyme immunoassay.Data analysis
Data were coded, entered and analyzed using IBM SPSS for
Windows, version 20.0 (IBM Corp., Armonk New York,
USA). Results are presented as counts (proportions) and
means with standard deviations (SD). Odds ratios (OR)
with their 95% confidence intervals (CI) served to investi-
gate the influence of various factors on the occurrence of
HBV infection. They were calculated by both univariate
and multivariate logistic regression analyses while adjusting
for potential confounders. We included in the multivariate
model the age and all variables with a p value ≤ 0.25 in
univariate analyses. For this purpose, we categorized some
variables into two groups: age (≤24 and > 24 years); marital
status (married and not married); number of pregnancies
(≤2 and > 2); past history of abortion (“yes” or “no”).
Educational level was classified as ‘low’ for women having a
primary level of education or less, and ‘high’ for those with
a secondary level of education or more. Profession was
categorized as ‘no job’ for housewives and ‘active’ for
salaried employees or traders. A p value < 0.05 was set as
statistically significant.
Table 2 Risk factors of HBV infection and markers of HBV
infectivity among pregnant women attending antenatal







Previous blood transfusion : Yes 4 1.2
Ever been scarified : Yes 59 19.2
Underwent excision : Yes 3 0.9
Ever been operated : Yes 7 2.2
Previous dental care : Yes 10 3.1
Family history of HBV infection : Yes 21 6.5
Vaccinated against HBV: No 4 1.2
History of HBV infection during previous
pregnancies: Yes
1 0.3
Number of pregnancies ever had
≤2 135 41.5
Noubiap et al. BMC Public Health  (2015) 15:454 Page 3 of 7Results
We recruited 325 pregnant women, the general back-
ground of whom is displayed in Table 1. Age ranged from
15 to 40 years with a mean of 24.4 (SD 5.6) years. Most of
our respondents (80%) were not beyond the primary school
and 313 (96.4%) women were housewives. Christians were
more represented (47.7%), more so as married women
(97.2%) (Table 1).
Risk factors for HBV infection are presented in Table 2.
The main factors reported were: history of ritual scarifi-
cations (19.2%), family history of known HBV infection
(6.5%), dental care (3.1%), and previous surgery (2.2%).
Only 4 women (1.2%) had been vaccinated against HBV.
The total number of pregnancies per woman ranged
from 1 to 16 with a mean of 3.6 (SD 2.6) pregnancies,
and 42 women (12.9%) had a past history of abortion.
The prevalence of HBV infection was 10.2% (33/325).
Among women positive to HBsAg, only 4 (12.1%) were also
positive to HBeAg (Table 2). Furthermore, 8 (2.5%) womenTable 1 Demographics of pregnant women attending
antenatal care in in the Guidiguis health district, December
2013-March 2014
Variable Number (N = 325) Percentage (%)
Age
≤24 years 172 52.9





















Salaried employee 6 1.8
Trader 6 1.8
≥3 190 58.5










HBe Antigen (N = 33)
Negative 29 87.9
Positive 4 12.1were HIV positive. Overall, 5 (1.5%) pregnant women were
co-infected with HIV and HBV. Factors independently as-
sociated with HBV infection included previous history of
blood transfusion (adjusted OR 12.59, 95% CI 1.46-108.89;
p = 0.021) and co-infection with HIV (adjusted OR 22.53,
95% CI 4.76-106.71; p < 0.0001). The other factors assessed
did not influence the occurence of HBV infection among
our participants (Table 3).
Discussion
We investigated the seroprevalence and factors associated
with HBV infection in a rural area of the Far North region
of Cameroon. The information gathered by this work may
contribute to improve knowledge on HBV infection epi-
demiology in pregnant women in that region, and to inform
local and national antenatal HBV screening and infant
immunization policies.
Table 3 Crude and adjusted correlates of HBV infection among pregnant women attending antenatal care in the
Guidiguis health district, December 2013-March 2014
Variable Crude odds ratio 95% CI p value Adjusted odds ratio* 95% CI p value
Age
≤24 years 0.81 0.40 – 1.69 0.590 0.50 0.19 – 1.30 0.115
≥25 years 1 1
Religion
Muslim 0.94 0.30 – 2.92 0.913
Christian 1.73 0.66 – 4.50 0.262
Other 1
Marital status
Married 0.79 0.09 – 6.62 0.827
Not married 1
Educational level
Low 0.92 0.38 – 2.22 0.854
High 1
Profession




Yes 9.36 1.27 – 68.76 0.028 12.59 1.46 – 108.89 0.021**
Ever been scarified
No 1
Yes 1.51 0.65 – 3.54 0.341
Underwent excision
No
Yes 1.11 1.07 – 1.16 0.725
Ever been operated
No
Yes 1.12 1.08 – 1.16 0.469
Previous dental care
No 1
Yes 0.98 0.12 – 8.01 0.987
Family history of HBV
No 1
Yes 0.43 0.55 – 3.27 0.411
Vaccinated against HBV
No 1
Yes 1.11 1.07 - 1.16 0.650
Number of pregnancies
≤2 1.57 0.76 – 3.22 0.223 2.60 0.97 – 6.95 0.058
>2 1 1
Past history of abortion
No 2.46 0.57 – 10.68 0.229 2.55 0.48 – 13.13 0.264
Yes 1 1
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Table 3 Crude and adjusted correlates of HBV infection among pregnant women attending antenatal care in the
Guidiguis health district, December 2013-March 2014 (Continued)
Concurrent HIV infection
No 1 1
Yes 17.20 3.90 – 75.80 <0.0001 22.53 4.76 – 106.71 <0.0001**
CI: confidence interval.
*Adjusted for age, history of blood transfusion, number of pregnancies, number of abortions and HIV status.
**p value < 0.05.
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with HBV in this rural area. According to WHO, the preva-
lence of HBV among pregnant women in this study is clas-
sified as high (≥8%) [9]. Our study adds to the various
endemicity data reported among pregnant women in sub-
Saharan African countries: 6.5% in Congo [14], 9.3% in
Kenya [15], 9.5% in Gabon [16], 10.7% in Burkina Faso [17],
10.9 % in Mauritania [18], 12.6% in Ghana [19], 13.8% in
Senegal [20], and 25% in Zimbabwe [21]. Prevalence of
HBV in this study conforms with the 9.7% prevalence rate
found among pregnant women in a semi-urban setting in
Buea (South West region of Cameroon) [12], but is greater
than the 7.7% and 7.85% reported in two studies conducted
in urban health facilities in Yaoundé, the capital city of
Cameroon [13,22]. Contrariwise, HBV prevalence in this
study was about half the 20.4% prevalence reported among
pregnant women in Tokombéré, another rural district in
the Far North region of Cameroon [23]. The HBV preva-
lence found in Tokombéré is surprisingly high, probably
the highest reported nationwide. Although our study and
the just-mentioned one were conducted in rural settings of
the Far North region of the country, the striking difference
between the two prevalences may be explained by the fact
that Tokombéré is a village situated near politically unstable
areas of Chad and Nigeria, both presenting a significant
rate of emigration and seemingly high HBV prevalence
(7-30%) [23,24].
MTCT of HBV is reported to be responsible for
more than one third of chronic HBV infections
globally [5], and perinatal infection is assumed to be a
major mode of transmission in high-prevalence areas
like most sub-Saharan African countries [6]. HBeAg
positivity is associated with a high risk of perinatal
transmission of HBV as children born to mothers
positive to both HBsAg and HBeAg have a 70-90%
chance of perinatal acquisition of HBV infection [7].
Compared to our results, the study conducted in
Tokombéré, reported a high rate of HBeAg and
elevated viremia among HBsAg-positives (22.7%),
suggesting a high rate of HBV perinatal transmission [23].
Another study conducted in an urban setting in
Cameroon also found a high rate of HBV infectivity,
with 28% of HBsAg-positive pregnant women being
HBeAg-positive [13]. These findings are consistent with
the results of a systematic literature review exploringthe risk of perinatal HBV transmission based on HBeAg
prevalence estimates from all regions of the world. It
revealed that in 2005, 22.7% to 29.9% of HBsAg-
positive women of reproductive age in Central sub-
Saharan Africa were HBeAg-positive [25]. Our study
found a lower rate of HBV infectivity, with a prevalence
of HBeAg among HBsAg-positive women of 12.1%. The
overall prevalence of HBeAg in our sample was 1.2%.
This suggests that the probability of HBV MTCT was
high only in a small proportion of our study popula-
tion. Another study in Yaoundé found that none of the
HBsAg-positive pregnant women with known HIV status
were positive to HBeAg, suggesting that perinatal trans-
mission plays a minor role in HBV burden in Cameroon
[22]. Interestingly, current recommendation of the
national immunization program of Cameroon to vaccinate
all newborn at 6, 10 and 14 weeks of age is probably based
on the evidence that horizontal transmission during early
childhood could be the most common mechanism of
HBV infection, as reported in other sub-Saharan African
countries [26-28]. The conflicting data on HBV infectivity
among pregnant women and MTCT in sub-Saharan
African countries call for further investigations.
The prevalence of HIV infection and HIV/HBV co-
infection were respectively 2.5% and 1.5%. This co-infection
rate is twice the 0.74% rate recently found among
urban pregnant women in Yaoundé [13], greater than
the 0.88% reported in Burkina Faso [29], similar to the
1.3% found in Northwest Ethiopia [30], but significantly
lower than the 4.2% rate reported in a study in Nigeria
[31]. We found that HIV infection was highly associ-
ated with HBV infection in our study population, with
HIV-infected women being more than 22 times more
likely to be co-infected with HBV than HIV-uninfected
ones. This finding is consistent with that of previous
survey conducted among blood donors in Edéa, Cameroon
[10]. This can be explained by the fact that HBV and HIV
share common modes of transmission. Moreover, it has
been reported that HIV/HBV co-infection facilitates
HBV replication and reactivation leading to higher
HBV-DNA levels and a reduced spontaneous clearance
of the virus [32].
We also found that previous history of blood transfu-
sion was associated with an increased risk of HBV in-
fection, as reported in previous studies among pregnant
Noubiap et al. BMC Public Health  (2015) 15:454 Page 6 of 7women [30,33]. This result stresses the need to improve
blood transfusion safety in our milieu.
Our study has some limitations. First, we used rapid diag-
nostic tests which are less sensitive than ELISA or PCR
tests, leading to possible underestimation of the prevalence
of assessed markers. Furthermore, we investigated HBV
infectivity based only on HBeAg, and we did not look for
anti-HBe antibodies and HBV viral load which are also im-
portant determinants of the HBV transmission. Despite
these shortcomings, this study provides relevant informa-
tion in a context of very limited epidemiological data on
HBV infection in Cameroon, especially among pregnant
women in the rural milieu.
Conclusion
Our study suggests a high prevalence of HBV infection
among pregnant women in a rural setting of the Far North
region of Cameroon. History of blood transfusion and HIV
infection are independently associated with the occurrence
of HBV infection in this setting. The relative low prevalence
of women positive to both HBsAg and HBeAg in the study
population suggests that perinatal transmission of HBV
might not be the major mode of HBV transmission in this
area. Further studies are needed to assess thoroughly the
burden and determinants of MTCT of HBV in this setting.
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